As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.
8 Analysts have issued a EyeGate Pharmaceuticals, Inc. forecast:
8 Analysts have issued a EyeGate Pharmaceuticals, Inc. forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -11 -11 |
512%
512%
|
|
| EBIT (Operating Income) EBIT | -11 -11 |
517%
517%
|
|
| Net Profit | -12 -12 |
549%
549%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
EyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes EGP-437 and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.
| Head office | United States |
| CEO | Brian Strem |
| Employees | 12 |
| Founded | 1998 |
| Website | kiorapharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


